Senores Pharmaceuticals has announced the acquisition of 14 Abbreviated New Drug Applications (ANDAs) from Dr. Reddy’s Laboratories and its affiliates through its wholly-owned subsidiary, Senores Pharmaceuticals, Inc., USA.

The acquisition includes 13 ANDAs that have already received approval from the US Food and Drug Administration (USFDA) and one ANDA that is currently pending approval.

The acquired ANDAs represent a significant market opportunity in the United States, with an estimated value of approximately USD 421 million as per IQVIA data (MAT December 2024) and around USD 1.13 billion according to the specialty data aggregator Symphony (MAT September 2024). The transaction will be funded using the proceeds from Senores Pharmaceuticals Limited’s Initial Public Offering (IPO), aligning with the objectives stated in its Red Herring Prospectus.

Commenting on the acquisition, Senores Pharmaceuticals Limited’s Managing Director, Swapnil Shah, stated that the acquisition covers various therapeutic areas, including controlled substances and general pharmaceutical products. The newly acquired portfolio allows the company to cater to a broad range of distribution channels, including government, retail, and specialty clinics.

He further emphasized that this expansion significantly enhances Senores Pharmaceuticals’ offerings in the US market and strengthens its presence in both regulated and semi-regulated global markets.

Senores Pharmaceuticals is a global pharmaceutical company focused on research-driven product development and manufacturing. It primarily serves markets in the US, Canada, and other regulated and emerging regions. The company’s portfolio includes 27 ANDAs and 21 CMO/CDMO commercial products approved for distribution in the United States. Additionally, it specializes in developing complex generics and supplying generic medicines to over 40 countries.

Senores Pharmaceuticals operates two formulation manufacturing facilities—one in Atlanta, USA, which is USFDA-approved and DEA/BAA compliant, and another in Chhatral, Ahmedabad, India, which is WHO-GMP approved for emerging markets. The company also has two active pharmaceutical ingredient (API) manufacturing units in India, located in Chhatral and Naroda. Senores Pharmaceuticals continues to invest in research and development across its three R&D centers—one in the US and two in India—to drive product innovation and differentiation.

This strategic acquisition is expected to enhance Senores Pharmaceuticals’ product pipeline and expand its market reach in key pharmaceutical sectors.